Prime Medicine initiates human in vivo DNA editing trial
Biotechnology firm Prime Medicine has performed the first direct in vivo DNA edit on a human patient to address Wilson’s disease.
U.S.-based biotechnology company Prime Medicine has announced the first successful application of its proprietary gene-editing technology directly within a human patient. The procedure targeted a participant suffering from Wilson’s disease, a rare genetic disorder characterized by the body’s inability to metabolize copper, leading to toxic accumulation in the liver and brain.
The clinical trial involves using a specialized platform to rewrite DNA sequences directly within the patient’s liver cells. Current treatment for the condition is limited to lifelong medication or liver transplantation, both of which carry significant risks and logistical challenges.
Chief Medical Officer Mohammed Asmal stated that the therapeutic goal is to provide a one-time, curative intervention that prevents irreversible organ damage. The company expects initial data regarding the safety and efficacy of the trial to be available by 2027.
Prime Medicine is positioning its platform to correct various types of genetic mutations while minimizing off-target modifications. The ongoing clinical investigation aims to determine if the technology is a viable, long-term solution for patients with genetic metabolic disorders.